Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: A review of the literature and a case report

Special Care in Dentistry

Volumn 30, Issue 2, 2010, Pages 77-82

  Narongroeknawin, Pongthorn ^a   Danila, Maria I ^a   Humphreys, Lewis G ^b   Barasch, Andrei ^c   Curtis, Jeffrey R ^a  

^a The University of Alabama at Birmingham   (United States)

^b Private Practice   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bisphosphonate; ONJ; Osteonecrosis; Osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; PARATHYROID HORMONE[1-34];

ARTICLE; BONE NECROSIS; BONE REGENERATION; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FOLLOW UP; HUMAN; JAW DISEASE; MALE; MIDDLE AGED; OSTEOARTHRITIS; OSTEOPOROSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TOOTH EXTRACTION; TOOTH IMPLANTATION;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; DENTAL IMPLANTS; DIPHOSPHONATES; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MAXILLARY DISEASES; MIDDLE AGED; OSTEOARTHRITIS; OSTEONECROSIS; OSTEOPOROSIS; TERIPARATIDE; TOOTH EXTRACTION;

EID: 77953576885     PISSN: 02751879     EISSN: 17544505     Source Type: Journal    
DOI: 10.1111/j.1754-4505.2009.00128.x     Document Type: Article

References (48)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
2. Brooks JK, Gilson AJ, Sindler AJ, et al. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Path Oral Radiol Endod 2007;103:780-786
3. Malden NJ, Pai AY. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J 2007;203:93-97
4. Bilezikian JP. Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-2281
5. Khan AA, Sandor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-490
6. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122: S33-45.
7. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22: 1479-1491
8. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
9. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822
10. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826-836
11. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423
12. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137:1144-1150
13. Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2009;38:5-9.
14. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23: 8580-8587
15. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zole-dronic acid. Haematologica 2006;91: 968-971
16. Pozzi S, Marcheselli R, Sacchi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007;48:56-64.
17. Ortega C, Faggiuolo R, Vormola R, et al. Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncol 2006;45:216-217
18. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Brit J Haematol 2006;134:620-623
19. Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009;140:61-66
20. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-441
21. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40.
22. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809
23. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99:1016-1024
24. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
25. Marx RE, Sawatari Y, Fortin M, Broumand V Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575
26. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-952
27. Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-1370
28. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
29. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761
30. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 1995;10:74-78
31. Duarte PM, de Vasconcelos Gurgel BC, Sallum AW, et al. Alendronate therapy may be effective in the prevention of bone loss around titanium implants inserted in estrogen-deficient rats. J Periodontol 2005;76:107-114
32. Narai S, Nagahata S. Effects of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants 2003;18:218-223
33. Chacon GE, Stine EA, Larsen PE, et al. Effect of alendronate on endosseous implant integration: an in vivo study in rabbits. J Oral Maxillofac Surg 2006;64:1005-1009
34. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21: 349-353
35. Expert Panel Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws. June 2004. (Accessed June 16, 2009, at http://www.ada. org/prof/resources/topics/topics-osteonecrosis-whitepaper.pdf.)
36. Magopoulos C, Karakinaris G, Telioudis Z, et al. Osteonecrosis of the jaws due to bis-phosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 2007;28:158-163
37. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 2006;132:114.
38. Bagán J, Blade J, Cozar JM, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-40.
39. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-145
40. Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21:1545-1548
41. Montefusco V, Gay F, Spina F, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphospho-nates. Leuk Lymphoma 2008;49:2156-2162
42. Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139:1674-1677
43. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 2007;78:584-594
44. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007;65:573-580
45. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357: 905-916
46. Kawane T, Takahashi S, Saitoh H, et al. Anabolic effects of recombinant human parathyroid hormone (1-84) and synthetic human parathyroid hormone (1-34) on the mandibles of osteopenic ovariectomized rats with maxillary molar extraction. Horm Metab Res 2002;34:293-302.
47. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003;89:180-190
48. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93:3785-3793